Upgrade to SI Premium - Free Trial

Astellas Pharma Inc Unsponsored Adr (ALPMY)

15.70 +0.22 (1.42%)

Chart
Today 6M 1Y 5Y

Latest Headlines

Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026 October 6, 2026 7:30 PM - PR NewsWire New Preliminary Real-World VEOZAH™ (fezolinetant) Data Highlights Improvements in Menopause-Related Symptoms and Sleep Outcomes October 2, 2026 8:00 AM - PR NewsWire Astellas begins Phase 3 trial of ASP2138 for gastric cancer August 24, 2026 7:30 PM - StreetInsider Astellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma August 24, 2026 7:30 PM - PR NewsWire CLSA Starts Astellas Pharma Inc (4503:JP) (ALPMY) at Outperform (2) August 18, 2026 8:25 AM - StreetInsider Astellas Pharma Inc (4503:JP) (ALPMY) PT Raised to JPY2,500 at JPMorgan August 17, 2026 2:31 AM - StreetInsider Full Article List